Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants

Trial Identifier: D9182C00002
Sponsor: AstraZeneca
NCTID:: NCT05070312
Start Date: August 2021
Primary Completion Date: February 2022
Study Completion Date: February 2022
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese Translation

Trial Locations

Country Location
CN Suzhou, CN, 215006